Eagle Pharmaceuticals Inc. (EGRX) Stock Price Down 1.3%
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares fell 1.3% during trading on Monday . The stock traded as low as $46.43 and last traded at $46.72, with a volume of 148,923 shares. The stock had previously closed at $47.34.
Several brokerages have recently commented on EGRX. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. Mizuho lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $66.00 to $47.00 in a research note on Monday, June 20th. Royal Bank Of Canada restated a “buy” rating and set a $78.00 price target on shares of Eagle Pharmaceuticals in a research note on Monday, June 13th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $98.00 price target on shares of Eagle Pharmaceuticals in a research note on Thursday, April 7th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $88.94.
The stock’s market cap is $740.05 million. The stock’s 50-day moving average price is $43.50 and its 200-day moving average price is $51.63.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.46 by $0.52. The company had revenue of $29.60 million for the quarter, compared to analysts’ expectations of $29.07 million. During the same period in the prior year, the company posted $1.31 EPS. The business’s revenue for the quarter was down 18.5% on a year-over-year basis. Equities research analysts anticipate that Eagle Pharmaceuticals Inc. will post $4.16 earnings per share for the current fiscal year.
In related news, major shareholder Proquest Management Llc sold 17,980 shares of the business’s stock in a transaction that occurred on Friday, May 13th. The shares were sold at an average price of $40.72, for a total transaction of $732,145.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
A number of hedge funds and institutional investors recently made changes to their positions in EGRX. OppenheimerFunds Inc. bought a new position in shares of Eagle Pharmaceuticals during the fourth quarter worth $6,104,000. Bank of Montreal Can raised its position in shares of Eagle Pharmaceuticals by 62.3% in the fourth quarter. Bank of Montreal Can now owns 119,902 shares of the specialty pharmaceutical company’s stock worth $10,632,000 after buying an additional 46,020 shares during the last quarter. Turner Investments L.P. bought a new position in shares of Eagle Pharmaceuticals during the fourth quarter worth $2,350,000. Russell Frank Co raised its position in shares of Eagle Pharmaceuticals by 38.7% in the fourth quarter. Russell Frank Co now owns 71,401 shares of the specialty pharmaceutical company’s stock worth $6,371,000 after buying an additional 19,938 shares during the last quarter. Finally, Century Capital Management LLC raised its position in shares of Eagle Pharmaceuticals by 34.4% in the fourth quarter. Century Capital Management LLC now owns 66,209 shares of the specialty pharmaceutical company’s stock worth $5,871,000 after buying an additional 16,942 shares during the last quarter.
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care, orphan diseases and oncology areas. Its commercial products include Argatroban Injection, Ryanodex (dantrolene sodium) for injectable suspension, Diclofenac sodium misoprostol and Docetaxel Injection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.